fludarabine has been researched along with allopurinol in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Jacobs, MI; Mantha, S; Savage, DG | 1 |
| Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J | 1 |
| Bosman, WM; Langenberg, JC; Ritchie, ED; van den Bremer, J | 1 |
1 trial(s) available for fludarabine and allopurinol
| Article | Year |
|---|---|
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine | 2012 |
5 other study(ies) available for fludarabine and allopurinol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Unusual leukemia presentations. Case 3. Type I IgGlambda cryoglobulinemia associated with chronic lymphocytic leukemia.
Topics: Allopurinol; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Diagnosis, Differential; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Vidarabine | 2005 |
Pathological fractures in a patient with chronic lymphatic leucaemia without disease progression.
Topics: Accidental Falls; Allopurinol; Antineoplastic Agents; Bone Marrow; Female; Femur; Fractures, Bone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Osteolysis; Pelvis; Positron-Emission Tomography; Radiography; Rituximab; Sacrum; Sodium Bicarbonate; Treatment Outcome; Vidarabine | 2015 |